Arcellx Inc (ACLX) Stock Forecast & Price Target

Compare

294 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ACLX Analyst Ratings

Strong Buy

16 Buy

2 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Arcellx

Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ACLX Stock 12 Month Forecast

Average Price Target

$112.29

▲(70.89% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Arcellx Inc in the last 3 months. The average price target is $112.29 with a high forecast of $130.00 and a low forecast of $88.00. The average price target represents a 70.89% change from the last price of $65.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"59":"$59","77":"$77","95":"$95","113":"$113","131":"$131"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$130.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$112.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$88.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[59,77,95,113,131],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.28,74.87384615384616,79.4676923076923,84.06153846153846,88.65538461538462,93.24923076923076,97.84307692307692,102.43692307692308,107.03076923076924,111.62461538461538,116.21846153846154,120.81230769230768,125.40615384615384,{"y":130,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.28,73.51153846153846,76.74307692307693,79.97461538461539,83.20615384615385,86.43769230769232,89.66923076923078,92.90076923076924,96.1323076923077,99.36384615384617,102.59538461538463,105.8269230769231,109.05846153846154,{"y":112.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.28,71.64307692307692,73.00615384615385,74.36923076923077,75.7323076923077,77.09538461538462,78.45846153846153,79.82153846153847,81.18461538461538,82.5476923076923,83.91076923076923,85.27384615384615,86.63692307692308,{"y":88,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":95.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.69,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.69,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.28,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$130.00

Average Price Target$112.29

Lowest Price Target$88.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yanan Zhu

Wells Fargo

$100

Buy

52.18%

Upside

Initiated

12/22/25

Wells starts Arcellx with Overweight on multiple myeloma potentialWells starts Arcellx with Overweight on multiple myeloma potential

Biren Amin

Piper Sandler

$115

Buy

75.01%

Upside

Reiterated

12/16/25

Arcellx Inc (ACLX) Gets a Buy from Piper Sandler

John Newman

Canaccord Genuity

$130

Buy

97.84%

Upside

Reiterated

12/16/25

Canaccord Genuity Reaffirms Their Buy Rating on Arcellx Inc (ACLX)

Geoff Meacham

Citi

$110

Buy

67.40%

Upside

Reiterated

12/09/25

Citi Sticks to Their Buy Rating for Arcellx Inc (ACLX)

Michael Schmidt

Guggenheim

$120

Buy

82.62%

Upside

Reiterated

12/08/25

Guggenheim Sticks to Its Buy Rating for Arcellx Inc (ACLX)

Cory Kasimov

Evercore ISI

$115

Buy

75.01%

Upside

Reiterated

12/08/25

Evercore ISI Keeps Their Buy Rating on Arcellx Inc (ACLX)

Sami Corwin

William Blair

Buy

―

Reiterated

12/08/25

Arcellx Inc's Promising Future: Buy Rating Backed by Strong Efficacy, Safety, and Strategic Partnerships

Emily Bodnar

H.C. Wainwright

$115

Buy

75.01%

Upside

Reiterated

12/08/25

Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Arcellx Inc

Gil Blum

Needham

$105

Buy

59.79%

Upside

Reiterated

12/08/25

Arcellx Inc's Anito-cel: Promising CAR-T Therapy with Superior Safety Profile and Market Readiness

Asthika Goonewardene

Truist Financial

Buy

―

Reiterated

12/08/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (NASDAQ: INCY), Fulcrum Therapeutics (NASDAQ: FULC) and Arcellx Inc (NASDAQ: ACLX)

Jason Gerberry

Bank of America Securities

$112

Buy

70.45%

Upside

Reiterated

12/07/25

Arcellx Inc's Promising iMMagine-1 Study and Strategic Plans Justify Buy Rating and $112 Price Target

Tyler Van Buren

TD Cowen

Buy

―

Initiated

12/07/25

Judah Frommer

Morgan Stanley

$111

Buy

68.92%

Upside

Reiterated

12/07/25

Optimistic Buy Rating for Arcellx Inc: Promising Anito-cel Therapy and Strategic Advancements

Stephen Willey

Stifel Nicolaus

$129→$127

Buy

93.27%

Upside

Reiterated

11/25/25

Stifel Nicolaus Sticks to Its Buy Rating for Arcellx Inc (ACLX)

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

Hold

―

Initiated

11/17/25

Arcellx initiated with a Peer Perform at Wolfe ResearchArcellx initiated with a Peer Perform at Wolfe Research

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yanan Zhu

Wells Fargo

$100

Buy

52.18%

Upside

Initiated

12/22/25

Wells starts Arcellx with Overweight on multiple myeloma potentialWells starts Arcellx with Overweight on multiple myeloma potential

Biren Amin

Piper Sandler

$115

Buy

75.01%

Upside

Reiterated

12/16/25

Arcellx Inc (ACLX) Gets a Buy from Piper Sandler

John Newman

Canaccord Genuity

$130

Buy

97.84%

Upside

Reiterated

12/16/25

Canaccord Genuity Reaffirms Their Buy Rating on Arcellx Inc (ACLX)

Geoff Meacham

Citi

$110

Buy

67.40%

Upside

Reiterated

12/09/25

Citi Sticks to Their Buy Rating for Arcellx Inc (ACLX)

Michael Schmidt

Guggenheim

$120

Buy

82.62%

Upside

Reiterated

12/08/25

Guggenheim Sticks to Its Buy Rating for Arcellx Inc (ACLX)

Cory Kasimov

Evercore ISI

$115

Buy

75.01%

Upside

Reiterated

12/08/25

Evercore ISI Keeps Their Buy Rating on Arcellx Inc (ACLX)

Sami Corwin

William Blair

Buy

―

Reiterated

12/08/25

Arcellx Inc's Promising Future: Buy Rating Backed by Strong Efficacy, Safety, and Strategic Partnerships

Emily Bodnar

H.C. Wainwright

$115

Buy

75.01%

Upside

Reiterated

12/08/25

Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Arcellx Inc

Gil Blum

Needham

$105

Buy

59.79%

Upside

Reiterated

12/08/25

Arcellx Inc's Anito-cel: Promising CAR-T Therapy with Superior Safety Profile and Market Readiness

Asthika Goonewardene

Truist Financial

Buy

―

Reiterated

12/08/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (NASDAQ: INCY), Fulcrum Therapeutics (NASDAQ: FULC) and Arcellx Inc (NASDAQ: ACLX)

Jason Gerberry

Bank of America Securities

$112

Buy

70.45%

Upside

Reiterated

12/07/25

Arcellx Inc's Promising iMMagine-1 Study and Strategic Plans Justify Buy Rating and $112 Price Target

Tyler Van Buren

TD Cowen

Buy

―

Initiated

12/07/25

Judah Frommer

Morgan Stanley

$111

Buy

68.92%

Upside

Reiterated

12/07/25

Optimistic Buy Rating for Arcellx Inc: Promising Anito-cel Therapy and Strategic Advancements

Stephen Willey

Stifel Nicolaus

$129→$127

Buy

93.27%

Upside

Reiterated

11/25/25

Stifel Nicolaus Sticks to Its Buy Rating for Arcellx Inc (ACLX)

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

Hold

―

Initiated

11/17/25

Arcellx initiated with a Peer Perform at Wolfe ResearchArcellx initiated with a Peer Perform at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcellx Inc

1 Month

xxx

Success Rate

19/26 ratings generated profit

Average Return

+4.77%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.08% of your transactions generating a profit, with an average return of +4.77% per trade.

3 Months

xxx

Success Rate

11/18 ratings generated profit

Average Return

+11.13%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +11.13% per trade.

1 Year

Jason GerberryBank of America Securities

Success Rate

15/22 ratings generated profit

Average Return

+30.13%

reiterated a buy rating 23 days ago

Copying Jason Gerberry's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +30.13% per trade.

2 Years

xxx

Success Rate

14/21 ratings generated profit

Average Return

+100.16%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +100.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACLX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ACLX has received 42 Buy Ratings, 5 Hold Ratings, and 1 Sell Ratings. ACLX average Analyst price target in the past 3 months is 112.29.

Each month's total comprises the sum of three months' worth of ratings.

ACLX Financial Forecast

ACLX Earnings Forecast

Next quarter’s earnings estimate for ACLX is -$1.06 with a range of -$1.22 to -$0.88. The previous quarter’s EPS was -$0.99. ACLX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ACLX has Performed in-line its overall industry.

ACLX Sales Forecast

Next quarter’s sales forecast for ACLX is $12.52M with a range of $0.00 to $58.00M. The previous quarter’s sales results were $4.95M. ACLX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ACLX has Performed in-line its overall industry.

ACLX Stock Forecast FAQ

What is ACLX’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcellx Inc’s 12-month average price target is 112.29.

What is ACLX’s upside potential, based on the analysts’ average price target?

Arcellx Inc has 70.89% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ACLX a Buy, Sell or Hold?

Arcellx Inc has a consensus rating of Strong Buy which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.

What is Arcellx Inc’s price target?

The average price target for Arcellx Inc is 112.29. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $130.00 ,the lowest forecast is $88.00. The average price target represents 70.89% Increase from the current price of $65.71.

What do analysts say about Arcellx Inc?

Arcellx Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of ACLX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Arcellx Inc (ACLX) Stock Forecast & Price Target

ACLX Analyst Ratings

ACLX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arcellx Inc

ACLX Analyst Recommendation Trends

ACLX Financial Forecast

ACLX Earnings Forecast

ACLX Sales Forecast

ACLX Stock Forecast FAQ

Detailed List of Analyst Forecasts